PHARMA MIX M 300

ACTIVE HALF-LIFE 5-6 days
CLASSIFICATION Anabolic Steroid
DOSAGE Men: 300-900 mg/week
ACNE Yes
WATER RETENTION Low
HBR No
HEPATOTOXICITY Low
AROMATIZATION No
CARRIER OIL Grapeseed Oil
MANUFACTURER Pharmacom Labs - US
LAB TEST See Document
WAREHOUSE USA Warehouse 4
SUBSTANCE Drostanolone Enanthate, Drostanolone Propionate

Introducing PHARMAMIX M 300, a powerful blend of two drostanolone esters?propionate and enanthate. This innovative formulation is designed for those looking to achieve high-quality lean muscle gains with a dense physique, while effectively minimizing unwanted subcutaneous water retention that can occur with long esters. Perfectly complements testosterone and trenbolone stacks (PHARMA SUST 300, 500, PHARMA 3-TREN) as well as extended-release testosterone and trenbolone esters (PHARMA TEST E300, E500, C250; PHARMA TREN E200, H100). We also offer a similarly successful product, PHARMA MIX 6, which has gained impressive popularity alongside PHARMA MIX 2.

First developed in 1959 by Syntex and released in 1970 as Masteron, drostanolone is a potent injectable anabolic steroid derived from dihydrotestosterone (DHT). Esteemed in medical literature for its robust anabolic effects combined with anti-estrogenic properties, drostanolone was FDA-approved for treating inoperable breast cancer in postmenopausal women, and its use has been recognized worldwide.

Biologically, Masteron mimics the effects of DHT, with its benefits most pronounced during cutting cycles. To maximize the advantages of this compound, users should maintain a lean physique. Non-aromatizing and offering a moderate diuretic effect similar to stanozolol, drostanolone enhances muscle definition, density, and overall aesthetics. Its lipolytic properties can facilitate a reduction in body fat by approximately 5-7%, making it a favored choice among track and field athletes and bodybuilders aiming to stay within their weight class.

While its bulking effects are modest, Masteron can produce gains comparable to those of Primobolan at higher doses, albeit with less dramatic results than other anabolic steroids. Notably, Masteron does not convert to estrogen and provides anti-estrogenic benefits by binding to aromatase, contributing to its application in breast cancer therapies.

In summary, drostanolone delivers effects akin to stanozolol without the common side effects associated with Winstrol. It does not increase tendon brittleness, deplete joint fluid, or significantly affect blood cholesterol levels. Therefore, for those undertaking a cutting cycle, drostanolone presents a safer and more effective option compared to stanozolol.